These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 21425995

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A, Tabata Y, Aoki K, Sada A, Ohki R, Nagatoishi S, Tsumoto K, Wang S, Otani Y, Ohwada T.
    Chem Pharm Bull (Tokyo); 2021 Jul 01; 69(7):681-692. PubMed ID: 33952867
    [Abstract] [Full Text] [Related]

  • 26. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.
    Popowicz GM, Dömling A, Holak TA.
    Angew Chem Int Ed Engl; 2011 Mar 14; 50(12):2680-8. PubMed ID: 21341346
    [Abstract] [Full Text] [Related]

  • 27. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H, Chemi G, Campiani G, Brogi S.
    Comput Biol Chem; 2019 Dec 14; 83():107105. PubMed ID: 31473433
    [Abstract] [Full Text] [Related]

  • 28. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A, Mohammed AA, Shaik TB.
    Expert Opin Ther Pat; 2012 Feb 14; 22(2):95-105. PubMed ID: 22316395
    [Abstract] [Full Text] [Related]

  • 29. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G, Yang D, Ma L, Li W, Hu L, Zeng L, Wu P, Duan L, Liu Z.
    Eur J Med Chem; 2018 Nov 05; 159():1-9. PubMed ID: 30253242
    [Abstract] [Full Text] [Related]

  • 30. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R, Zhou J, Qin L, Chen Y, Huang Y, Liu H, Su Z.
    Biochemistry; 2017 Jun 27; 56(25):3273-3282. PubMed ID: 28581721
    [Abstract] [Full Text] [Related]

  • 31. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR.
    Chem Biol Drug Des; 2015 Aug 27; 86(2):180-9. PubMed ID: 25388787
    [Abstract] [Full Text] [Related]

  • 32. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
    Lee XA, Verma C, Sim AYL.
    Proteins; 2017 Aug 27; 85(8):1493-1506. PubMed ID: 28425639
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP, Fitzgerald R, Fischer PM.
    Semin Cancer Biol; 2010 Feb 27; 20(1):10-8. PubMed ID: 19897042
    [Abstract] [Full Text] [Related]

  • 37. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
    Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL.
    Cell Death Differ; 2008 May 27; 15(5):841-8. PubMed ID: 18219319
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L.
    Expert Opin Ther Pat; 2010 Feb 27; 20(2):179-91. PubMed ID: 20100001
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.